MA43445B1 - Modified antibodies binding to human fcrn and methods of use - Google Patents

Modified antibodies binding to human fcrn and methods of use

Info

Publication number
MA43445B1
MA43445B1 MA43445A MA43445A MA43445B1 MA 43445 B1 MA43445 B1 MA 43445B1 MA 43445 A MA43445 A MA 43445A MA 43445 A MA43445 A MA 43445A MA 43445 B1 MA43445 B1 MA 43445B1
Authority
MA
Morocco
Prior art keywords
methods
human fcrn
modified antibodies
antibodies binding
fcrn
Prior art date
Application number
MA43445A
Other languages
French (fr)
Other versions
MA43445A1 (en
Inventor
Guido Hartmann
Joerg Thomas Regula
Matthias Rueth
Tilman Schlothauer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority claimed from PCT/EP2014/058417 external-priority patent/WO2014177460A1/en
Publication of MA43445A1 publication Critical patent/MA43445A1/en
Publication of MA43445B1 publication Critical patent/MA43445B1/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne l'utilisation d'un anticorps comportant une région fc présentant une liaison nulle à fcrn pour le transport d'un ligand soluble du récepteur, à partir de l'œil à travers la barrière hémato-oculaire dans la circulation sanguine.The present invention relates to the use of an antibody comprising an fc region exhibiting zero binding to fcrn for the transport of a soluble ligand of the receptor from the eye through the blood-ocular barrier into the bloodstream.

MA43445A 2014-04-25 2014-04-25 Modified antibodies binding to human fcrn and methods of use MA43445B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/058417 WO2014177460A1 (en) 2013-04-29 2014-04-25 Human fcrn-binding modified antibodies and methods of use

Publications (2)

Publication Number Publication Date
MA43445A1 MA43445A1 (en) 2019-07-31
MA43445B1 true MA43445B1 (en) 2021-03-31

Family

ID=67439949

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43445A MA43445B1 (en) 2014-04-25 2014-04-25 Modified antibodies binding to human fcrn and methods of use

Country Status (1)

Country Link
MA (1) MA43445B1 (en)

Also Published As

Publication number Publication date
MA43445A1 (en) 2019-07-31

Similar Documents

Publication Publication Date Title
EA201501063A1 (en) CONNECTING HUMAN FcRn MODIFIED ANTIBODIES AND METHODS OF THEIR APPLICATION
CY1124190T1 (en) ANTI-CTLA4 MONOCLONAL ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, PHARMACEUTICAL COMPOSITION AND USE
MA43028B1 (en) Bispecific antibodies for pd1 and tim3
WO2014055897A3 (en) Human monoclonal anti-pd-l1 antibodies and methods of use
MA42542B1 (en) Molecules Binding to pd-1 and Corresponding Methods of Use
WO2017015623A3 (en) Multivalent and multispecific gitr-binding fusion proteins
CL2015002756A1 (en) Bispecific fc molecules
EA201691438A1 (en) ANTIBODY WHICH IS CONNECTED WITH ERBB-2 AND ERBB-3
EA201890064A1 (en) SYSTEM OF CAPACITIES AND THEIR CONNECTIONS
MA40913A (en) ANTIBODY-DRUG CONJUGATES
MA44334A (en) ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST
NZ723858A (en) Anti-human ox40l antibodies, uses & methods
RU2017129721A (en) ANTIBODIES AGAINST αβTCR
MA38797A1 (en) Therapeutic fusion protein
EA201890082A1 (en) EPITOPE ANTIBODIES
MX2023006415A (en) Antibodies, uses & methods.
EP3705494A3 (en) Antibodies against frizzled proteins and methods of use thereof
MA38816B1 (en) Sulfamidase modified and its production
EP3608339A4 (en) Antibody fc variants for improving blood half-life
EA201691212A1 (en) NEW ANTIBODY AGAINST NETRINE-1
MX2020005364A (en) Anti-ox40 antibodies and uses thereof.
MA38161A1 (en) Anti-bmp-6 Antibody
EA202090084A1 (en) NEW THERAPEUTIC ENZYME Fusion PROTEIN AND ITS APPLICATION
MA46988A1 (en) Liquid formulation of anti-tnf alpha antibodies
EA201892071A1 (en) METHOD OF PREVENTION OF THE DISEASE "TRANSPLANTATE AGAINST THE OWNER"